Photo credit: www.sciencedaily.com
A team of researchers has discovered a promising new approach to decelerate the advancement of lung fibrosis and other fibrotic diseases by targeting Piezo2, a receptor that detects mechanical forces within tissues, such as stress, strain, and stiffness. This breakthrough, detailed in a study published in The American Journal of Pathology by Elsevier, provides insights into the mechanisms underlying pulmonary fibrotic diseases and identifies new therapeutic targets that could enhance patient outcomes.
Pulmonary fibrotic diseases encompass a range of disorders that significantly impact health, with some leading to serious outcomes. Among these, idiopathic pulmonary fibrosis (IPF) stands out as an aggressive condition, characterized by a median survival of just 2.9 years post-diagnosis. This disease leads to notable mechanical changes in the lungs, including increased tissue stiffness, thereby impeding the lungs’ ability to function properly during breathing.
Piezo channels, which emerged as a focus in biomedical research following the 2021 Nobel Prize in Medicine awarded to Dr. Ardem Patapoutian for his 2010 discovery, are known for their sensitivity to mechanical signals. Although there has been burgeoning interest in understanding their functions outside of neuronal signaling, literature addressing their role in fibrotic lung diseases has been sparse. In an effort to comprehend how mechanical forces contribute to pulmonary fibrosis, researchers studied the involvement of Piezo2 using human tissue samples from IPF patients, preclinical mouse models, lung fibroblast cell cultures, and RNA sequencing datasets from existing studies.
The researchers made several noteworthy findings:
- Piezo2 gene expression is significantly elevated in lung tissues from IPF patients as well as in various mouse models of lung fibrosis.
- The protein is also expressed at high levels in primary human lung fibroblasts, which are crucial in the formation of fibrosis by proliferating and producing matrix proteins that contribute to scar formation.
- When lung fibroblasts are cultured on stiffer surfaces, they exhibit a more profibrotic behavior, including increased proliferation, matrix protein secretion, and differentiation into myofibroblasts, which are responsible for scar tissue development.
- Using RNA silencing techniques or a peptide inhibitor to disrupt Piezo2 function effectively curtail the profibrotic programming of these cells by preventing their response to environmental stiffness.
Dr. Patricia J. Sime, a lead investigator from the Division of Pulmonary Disease and Critical Care Medicine at Virginia Commonwealth University, expressed enthusiasm regarding these findings: “Our research indicates that targeting the expression or function of Piezo2 holds potential as a novel therapeutic strategy for lung fibrosis and related diseases, particularly given the pressing need for new treatment options within this medical area.”
Although treatments like nintedanib and pirfenidone have been introduced for certain fibrotic lung diseases, effectively managing pulmonary fibrosis remains difficult. This complexity is partly due to the various pathways activated in lung cells that promote a profibrotic phenotype, making it challenging to rely on single-pathway interventions to halt disease progression.
Dr. Margaret A.T. Freeberg, the study’s first author, noted the difficulties in treating certain types of lung fibrosis, particularly IPF, which often tends to evolve unfavorably. While current therapies can slow progression, they are not always sufficient to stop it entirely. “The convoluted network of profibrotic pathways necessitates the exploration of new therapeutic targets, such as Piezo2, which could prevent the reprogramming of fibroblasts in our battle against fibrosis,” she commented.
In conclusion, Dr. Sime highlighted the significance of mechanical forces and Piezo2 as a critical target for inhibiting fibrotic reprogramming in lung cells. “Our findings underscore the potential of Piezo2 as a key therapeutic target that, alone or in combination with existing treatments, may slow pulmonary fibrosis progression. Investigational drugs that focus on this pathway may also benefit from orphan drug designations by the FDA, potentially expediting their development and appealing to pharmaceutical companies.”
Source
www.sciencedaily.com